Search

Objective: To study Efficacy of tenofovir in the treatment of chronic hepatitis B and its effect on serum Hyaluronic acid (HA), laminin (LN), type IV collagen (IV - C), a former Ⅲ type collagen peptide (PC - III). Methods: 101 patients with chronic hepatitis B who were treated in our hospital from January 2018 to January 2020 were selected for this study. They were divided into experimental group (n=51) and control group (n=50) by random number table method. The control group received entecavir treatment and the experimental group received tenofovir treatment. Clinical efficacy, changes in serum HA, LN, IV-C, PC-III, HBV-DNA, hepatitis B surface antigen (HBsAg), alanine aminotransferase (ALT), aspartate aminotransferase (AST) levels and the incidence of adverse drug reactions were compared between the two groups. Results: After treatment, the total effective rate between the two groups was significantly different (P<0.05). Compared with before treatment, there were no significant differences in serum HA, LN, IV-C and PC-III levels between the experimental group and the control group. After treatment, the serum levels of HA, LN, IV-C and PC-III in experimental group and control group decreased with time, and the levels in experimental group were lower than those in control group, the differences were significant (P<0.05). Compared with before treatment, serum HBV-DNA and HBsAg levels of the experimental group and the control group were not significantly different. After treatment, the levels of serum HBV-DNA and HBsAg in experimental group and control group decreased with the passage of time, and the difference was significant (P<0.05). Compared with before treatment, there was no significant difference in serum ALT and AST levels between the experimental group and the control group. After treatment, the serum levels of ALT and AST in experimental group and control group decreased with the passage of time, and the levels in experimental group were lower than those in control group, the difference was significant (P<0.05). The total incidence of ADR in the two groups was 7.84% and 10.00% (P>0.05), respectively. Conclusion: The effect of tenofovir on chronic hepatitis B may be related to its effective improvement of serum THA, LN, IV-C and PC-III levels. [ABSTRACT FROM AUTHOR]

Objective: To study Efficacy of tenofovir in the treatment of chronic hepatitis B and its effect on serum Hyaluronic acid（HA), laminin（LN), type IV collagen（IV-C), a former Ⅲ type collagen peptide（PC-III). Methods: 101 patients with chronic hepatitis B who were treated in our hospital from January 2018 to January 2020 were selected for this study. They were divided into experimental group（n=51） and control group（n=50） by random number table method. The control group received entecavir treatment and the experimental group received tenofovir treatment. Clinical efficacy, changes in serum HA, LN, IV-C, PC-III, HBV-DNA, hepatitis B surface antigen（HBs Ag), alanine aminotransferase（ALT), aspartate aminotransferase（AST） levels and the incidence of adverse drug reactions were compared between the two groups. Results: After treatment, the total effective rate between the two groups was significantly different（P<0.05). Compared with before treatment, there were no significant differences in serum HA, LN, IV-C and PC-III levels between the experimental group and the control group. After treatment, the serum levels of HA, LN, IV-C and PC-III in experimental group and control group decreased with time, and the levels in experimental group were lower than those in control group,the differences were significant（P<0.05). Compared with before treatment, serum HBV-DNA and HBs Ag levels of the experimental group and the control group were not significantly different. After treatment, the levels of serum HBV-DNA and HBs Ag in experimental group and control group decreased with the passage of time, and the difference was significant（P<0.05). Compared with before treatment, there was no significant difference in serum ALT and AST levels between the experimental group and the control group. After treatment, the serum levels of ALT and AST in experimental group and control group decreased with the passage of time, and the levels in experimental group were lower than those in control group, the difference was significant（P<0.05). The total incidence of ADR in the two groups was 7.84% and 10.00%（P>0.05), respectively. Conclusion: The effect of tenofovir on chronic hepatitis B may be related to its effective improvement of serum THA, LN, IV-C and PC-III levels [ABSTRACT FROM AUTHOR]